A fusion protein of the estrogen receptor (ER) and nuclear receptor corepressor (NCoR) strongly inhibits estrogen-dependent responses in breast cancer cells
- PMID: 10598586
- DOI: 10.1210/mend.13.12.0394
A fusion protein of the estrogen receptor (ER) and nuclear receptor corepressor (NCoR) strongly inhibits estrogen-dependent responses in breast cancer cells
Abstract
Nuclear receptor corepressor (NCoR) mediates repression (silencing) of basal gene transcription by nuclear receptors for thyroid hormone and retinoic acid. The goal of this study was to create novel estrogen receptor (ER) mutants by fusing transferable repressor domains from the N-terminal region of NCoR to a functional ER fragment. Three chimeric NCoR-ER proteins were created and shown to lack transcriptional activity. These fusion proteins silenced basal transcription of the ERE2-tk-Luc reporter gene and inhibited the activity of co-transfected wild-type ER (wtER), indicating that they possess dominant negative activity. One of the fusion proteins (CDE-RD1), containing the ER DNA-binding and ligand-binding domains linked to the NCoR repressor domain (RD1), was selected for detailed examination. Its hormone affinity, intracellular localization, and level of expression in transfected cells were similar to wtER, and it bound to the estrogen response element (ERE) DNA in gel shift assays. Glutathione-S-transferase pull-down assays showed that CDE-RD1 retains the ability to bind to steroid receptor coactivator-1. Introduction of a DNA-binding domain mutation into the CDE-RD1 fusion protein eliminated silencing and dominant negative activity. Thus, the RD1 repressor domain prevents transcriptional activation despite the apparent ability of CDE-RD1 to bind DNA, ligand, and coactivators. Transcriptional silencing was incompletely reversed by trichostatin A, suggesting a histone deacetylase-independent mechanism for repression. CDE-RD1 inhibited ER-mediated transcription in T47D and MDA-MB-231 breast cancer cells and repressed the growth of T47D cells when delivered to the cells by a retroviral vector. These ER-NCoR fusion proteins provide a novel means for inhibiting ER-mediated cellular responses, and analogous strategies could be used to create dominant negative mutants of other transcription factors.
Similar articles
-
Differential recruitment of coregulator proteins steroid receptor coactivator-1 and silencing mediator for retinoid and thyroid receptors to the estrogen receptor-estrogen response element by beta-estradiol and 4-hydroxytamoxifen in human breast cancer.J Clin Endocrinol Metab. 2004 Jan;89(1):375-83. doi: 10.1210/jc.2003-031048. J Clin Endocrinol Metab. 2004. PMID: 14715875
-
Estrogen response element-dependent regulation of transcriptional activation of estrogen receptors alpha and beta by coactivators and corepressors.J Mol Endocrinol. 2004 Oct;33(2):387-410. doi: 10.1677/jme.1.01541. J Mol Endocrinol. 2004. PMID: 15525597
-
A novel natural mutation in the thyroid hormone receptor defines a dual functional domain that exchanges nuclear receptor corepressors and coactivators.Mol Endocrinol. 1998 Dec;12(12):1888-902. doi: 10.1210/mend.12.12.0201. Mol Endocrinol. 1998. PMID: 9849963
-
Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action.Recent Prog Horm Res. 1997;52:141-64; discussion 164-5. Recent Prog Horm Res. 1997. PMID: 9238851 Review.
-
Protein coregulators that mediate estrogen receptor function.Reprod Fertil Dev. 2001;13(4):221-9. doi: 10.1071/rd01023. Reprod Fertil Dev. 2001. PMID: 11800161 Review.
Cited by
-
SIAH ubiquitin ligases regulate breast cancer cell migration and invasion independent of the oxygen status.Cell Cycle. 2015;14(23):3734-47. doi: 10.1080/15384101.2015.1104441. Cell Cycle. 2015. PMID: 26654769 Free PMC article.
-
Inhibition of growth of cervical cancer cells using a dominant negative estrogen receptor gene.Gynecol Oncol. 2007 Feb;104(2):276-80. doi: 10.1016/j.ygyno.2006.10.015. Epub 2006 Nov 29. Gynecol Oncol. 2007. PMID: 17137618 Free PMC article.
-
Transcriptional targeting of gene expression in breast cancer by the promoters of protein regulator of cytokinesis 1 and ribonuclease reductase 2.Exp Mol Med. 2008 Jun 30;40(3):345-53. doi: 10.3858/emm.2008.40.3.345. Exp Mol Med. 2008. PMID: 18587273 Free PMC article.
-
High-throughput cell-based screening reveals a role for ZNF131 as a repressor of ERalpha signaling.BMC Genomics. 2008 Oct 11;9:476. doi: 10.1186/1471-2164-9-476. BMC Genomics. 2008. PMID: 18847501 Free PMC article.
-
Gene therapy of benign gynecological diseases.Adv Drug Deliv Rev. 2009 Aug 10;61(10):822-35. doi: 10.1016/j.addr.2009.04.023. Epub 2009 May 13. Adv Drug Deliv Rev. 2009. PMID: 19446586 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous